Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Neurotox Res ; 39(5): 1430-1439, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34191265

RESUMO

Long-term exposure to different types of chemicals is hazardous to human health. Di(2-ethylhexyl) phthalate (DEHP) could exert pleiotropic deleterious effects on nervous systems. Mono(2-ethylhexyl) phthalate (MEHP), as one of the most toxic metabolites of DEHP, may have similar effects on nervous systems. However, no effects of MEHP on neural circuits have been reported. To uncover the regulation of MEHP on neural transmission, the functional changes of neural excitability and synaptic plasticity of projection neurons (PNs) have been assessed. In the current study, we recorded the action potentials (APs), stimulate action potentials (sti-APs), mini excitement postsynaptic current (mEPSC), calcium currents, and sodium currents from PNs of isolated whole brain of Drosophila model utilizing patch clamp recordings. We found that MEHP-300 (at the concentration of 300 µM), but not MHEP-100 (at the concentration of 100 µM), significantly decreased the frequency and amplitude of APs. Besides, the amplitude and anti-amplitude of sti-APs were reduced with the application of MEHP-300. Meanwhile, MEHP-300 reduced the frequency of mEPSC, but not the amplitude. Furthermore, MEHP-300 reduced the peak current densities of sodium and calcium channels. Therefore, our results indicated that MEHP could alter the neural excitability and synaptic plasticity of PNs by inhibiting the ion channels activities, revealing the potential modulation of MEHP on neural transmission of PNs.


Assuntos
Antenas de Artrópodes/efeitos dos fármacos , Dietilexilftalato/análogos & derivados , Plasticidade Neuronal/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Transmissão Sináptica/efeitos dos fármacos , Animais , Antenas de Artrópodes/fisiologia , Dietilexilftalato/toxicidade , Relação Dose-Resposta a Droga , Drosophila , Potenciais Pós-Sinápticos Excitadores/efeitos dos fármacos , Potenciais Pós-Sinápticos Excitadores/fisiologia , Plasticidade Neuronal/fisiologia , Neurônios/fisiologia , Transmissão Sináptica/fisiologia
2.
J Immunol ; 200(5): 1889-1900, 2018 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-29352002

RESUMO

Dysregulation of the immune barrier function of the intestinal epithelium can often result in dysbiosis. In this study we report a novel role of intestinal epithelial cell (IEC)-derived liver kinase B1 (LKB1) in suppressing colitogenic microbiota. IEC-specific deletion of LKB1 (LKB1ΔIEC) resulted in an increased susceptibility to dextran sodium sulfate (DSS)-induced colitis and a definitive shift in the composition of the microbial population in the mouse intestine. Importantly, transfer of the microbiota from LKB1ΔIEC mice was sufficient to confer increased susceptibility to DSS-induced colitis in wild-type recipient mice. Collectively, the data indicate that LKB1 deficiency in intestinal epithelial cells nurtures the outgrowth of colitogenic bacteria in the commensal community. In addition, LKB1 deficiency in the intestinal epithelium reduced the production of IL-18 and antimicrobial peptides in the colon. Administration of exogenous IL-18 restored the expression of antimicrobial peptides, corrected the outgrowth of several bacterial genera, and rescued the LKB1ΔIEC mice from increased sensitivity to DSS challenge. Taken together, our study reveals an important function of LKB1 in IECs for suppressing colitogenic microbiota by IL-18 expression.


Assuntos
Células Epiteliais/imunologia , Mucosa Intestinal/imunologia , Intestinos/imunologia , Microbiota/imunologia , Proteínas Serina-Treonina Quinases/imunologia , Proteínas Quinases Ativadas por AMP , Animais , Colite/induzido quimicamente , Colite/imunologia , Colo/efeitos dos fármacos , Colo/imunologia , Sulfato de Dextrana/farmacologia , Disbiose/imunologia , Interleucina-18/imunologia , Intestinos/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL
3.
J Exp Med ; 214(10): 3051-3066, 2017 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-28821568

RESUMO

Although genetic polymorphisms in the LRRK2 gene are associated with a variety of diseases, the physiological function of LRRK2 remains poorly understood. In this study, we report a crucial role for LRRK2 in the activation of the NLRC4 inflammasome during host defense against Salmonella enteric serovar Typhimurium infection. LRRK2 deficiency reduced caspase-1 activation and IL-1ß secretion in response to NLRC4 inflammasome activators in macrophages. Lrrk2-/- mice exhibited impaired clearance of pathogens after acute S. Typhimurium infection. Mechanistically, LRRK2 formed a complex with NLRC4 in the macrophages, and the formation of the LRRK2-NLRC4 complex led to the phosphorylation of NLRC4 at Ser533. Importantly, the kinase activity of LRRK2 is required for optimal NLRC4 inflammasome activation. Collectively, our study reveals an important role for LRRK2 in the host defense by promoting NLRC4 inflammasome activation.


Assuntos
Proteínas Reguladoras de Apoptose/fisiologia , Proteínas de Ligação ao Cálcio/fisiologia , Inflamassomos/imunologia , Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina/fisiologia , Salmonelose Animal/imunologia , Salmonella typhimurium/imunologia , Animais , Caspase 1/fisiologia , Inflamassomos/fisiologia , Interleucina-1beta/fisiologia , Macrófagos/fisiologia , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fosforilação
4.
J Neuroinflammation ; 12: 122, 2015 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-26104799

RESUMO

BACKGROUND: Aggregated forms of amyloid-ß (Aß) peptides are important triggers for microglial activation, which is an important pathological component in the brains of Alzheimer's patients. Cu(II) ions are reported to be coordinated to monomeric Aß, drive Aß aggregation, and potentiate Aß neurotoxicity. Here we investigated whether Cu(II) binding modulates the effect of Aß on microglial activation and the subsequent neurotoxicity. METHODS: Aß peptides were incubated with Cu(II) at an equimolar ratio to obtain the Cu(II)-Aß complex. Primary and BV-2 microglial cells were treated with Cu(II)-Aß, Aß, or Cu(II). The tumor necrosis factor-α (TNF-α) and nitric oxide levels in the media were determined. Extracellular hydrogen peroxide was quantified by a fluorometric assay with Amplex Red. Mitochondrial superoxide was detected by MitoSOX oxidation. RESULTS: Incubation of Cu(II) with Aß confers different chemical properties on the resulting complex. At the subneurotoxic concentrations, Cu(II)-Aß (but not Aß or Cu(II) alone) treatment induced an activating morphological phenotype of microglia and induced the microglial release of TNF-α and nitric oxide as well as microglia-mediated neuronal damage. Cu(II)-Aß-triggered microglial activation was blocked by nuclear factor (NF)-κB inhibitors and was accompanied with NF-κB activation. Moreover, Cu(II)-Aß induced hydrogen peroxide release, which was not affected by NADPH oxidase inhibitors. Mitochondrial superoxide production was increased after Cu(II)-Aß stimulation. N-acetyl-cysteine, a scavenger of reactive oxygen species (ROS), inhibited Cu(II)-Aß-elicited microglial release of TNF-α and nitric oxide as well as the microglia-mediated neurotoxic effect. CONCLUSION: Our observations suggest that Cu(II) enhances the effect of Aß on microglial activation and the subsequent neurotoxicity. The Cu(II)-Aß-triggered microglial activation involves NF-κB activation and mitochondrial ROS production.


Assuntos
Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/farmacologia , Cobre/farmacologia , Microglia/efeitos dos fármacos , Animais , Linhagem Celular , Sequestradores de Radicais Livres/farmacologia , Humanos , Peróxido de Hidrogênio/metabolismo , Ativação de Macrófagos/efeitos dos fármacos , Camundongos , NADPH Oxidases/antagonistas & inibidores , NF-kappa B/antagonistas & inibidores , Neurônios/efeitos dos fármacos , Óxido Nítrico/metabolismo , Superóxidos/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
5.
Toxicol Appl Pharmacol ; 276(2): 95-103, 2014 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-24530511

RESUMO

Microglia-mediated neuroinflammation and the associated neuronal damage play critical roles in the pathogenesis of neurodegenerative disorders. Evidence shows an elevated concentration of extracellular copper(II) in the brains of these disorders, which may contribute to neuronal death through direct neurotoxicity. Here we explored whether extracellular copper(II) triggers microglial activation. Primary rat microglia and murine microglial cell line BV-2 cells were cultured and treated with copper(II). The content of tumor necrosis factor-α (TNF-α) and nitric oxide in the medium was determined. Extracellular hydrogen peroxide was quantified by a fluorometric assay with Amplex Red. Mitochondrial superoxide was measured by MitoSOX oxidation. At subneurotoxic concentrations, copper(II) treatment induced a dose- and time-dependent release of TNF-α and nitric oxide from microglial cells, and caused an indirect, microglia-mediated neurotoxicity that was blocked by inhibition of TNF-α and nitric oxide production. Copper(II)-initiated microglial activation was accompanied with reduced IкB-α expression as well as phosphorylation and translocation of nuclear factor-κB (NF-κB) p65 and was blocked by NF-κB inhibitors (BAY11-7082 and SC-514). Moreover, copper(II) treatment evoked a rapid release of hydrogen peroxide from microglial cells, an effect that was not affected by NADPH oxidase inhibitors. N-acetyl-cysteine, a scavenger of reactive oxygen species (ROS), abrogated copper(II)-elicited microglial release of TNF-α and nitric oxide and subsequent neurotoxicity. Importantly, mitochondrial production of superoxide, paralleled to extracellular release of hydrogen peroxide, was induced after copper(II) stimulation. Our findings suggest that extracellular copper(II) at subneurotoxic concentrations could trigger NF-κB-dependent microglial activation and subsequent neurotoxicity. NADPH oxidase-independent, mitochondria-derived ROS may be involved in this activation.


Assuntos
Cobre/toxicidade , Microglia/efeitos dos fármacos , Mitocôndrias/efeitos dos fármacos , NF-kappa B/fisiologia , Espécies Reativas de Oxigênio/metabolismo , Animais , Células Cultivadas , Humanos , Camundongos , Microglia/metabolismo , Mitocôndrias/metabolismo , NADPH Oxidases/fisiologia , Óxido Nítrico/biossíntese , Ratos , Ratos Sprague-Dawley , Superóxidos/metabolismo , Fator de Necrose Tumoral alfa/biossíntese
6.
Toxicol Appl Pharmacol ; 264(1): 65-72, 2012 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-22842334

RESUMO

The strategy of dual binding site acetylcholinesterase (AChE) inhibition along with metal chelation may represent a promising direction for multi-targeted interventions in the pathophysiological processes of Alzheimer's disease (AD). In the present study, two derivatives (ZLA and ZLB) of a potent dual binding site AChE inhibitor bis-(-)-nor-meptazinol (bis-MEP) were designed and synthesized by introducing metal chelating pharmacophores into the middle chain of bis-MEP. They could inhibit human AChE activity with IC(50) values of 9.63µM (for ZLA) and 8.64µM (for ZLB), and prevent AChE-induced amyloid-ß (Aß) aggregation with IC(50) values of 49.1µM (for ZLA) and 55.3µM (for ZLB). In parallel, molecular docking analysis showed that they are capable of interacting with both the catalytic and peripheral anionic sites of AChE. Furthermore, they exhibited abilities to complex metal ions such as Cu(II) and Zn(II), and inhibit Aß aggregation triggered by these metals. Collectively, these results suggest that ZLA and ZLB may act as dual binding site AChEIs with metal-chelating potency, and may be potential leads of value for further study on disease-modifying treatment of AD.


Assuntos
Peptídeos beta-Amiloides/efeitos dos fármacos , Quelantes/farmacologia , Inibidores da Colinesterase/farmacologia , Meptazinol/análogos & derivados , Meptazinol/farmacologia , Acetilcolinesterase/efeitos dos fármacos , Acetilcolinesterase/metabolismo , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/fisiopatologia , Peptídeos beta-Amiloides/metabolismo , Animais , Sítios de Ligação , Quelantes/administração & dosagem , Quelantes/química , Inibidores da Colinesterase/administração & dosagem , Inibidores da Colinesterase/química , Cobre/metabolismo , Humanos , Concentração Inibidora 50 , Meptazinol/administração & dosagem , Camundongos , Zinco/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...